Purpose: The purpose of this study was to evaluate baseline RRM2 protein and gene expression in tumors of patients receiving 3-AP. Methods: Tumor blocks from patients enrolled in phase I and II clinical studies using 3-AP, were evaluated for RRM2 gene and protein expression by quantitative real time polymerase chain reaction (Q-RTPCR) and automated quantitative analysis (AQUA). Results: Esophageal and gastric cancers overexpressed RRM2 protein when compared to prostate cancer (Z-score, 0.68 ± 0.94 SD, vs 0.41 ± 0.84 SD, respectively; p = 0.04). Esophageal and gastric cancers also overexpressed RRM2 mRNA when compared to prostate cancer (relative gene expression 2.56 ± 1.49 SD, vs 0.29 ± 0.20 SD, respectively; p = 0.02). Protein and gene expression were moderately associated (Spearman's rank correlation = 0.30; p = 0.12). Conclusion: RRM2 gene and protein expression varies by tumor type.
|Number of pages||8|
|Journal||Cancer Chemotherapy and Pharmacology|
|State||Published - Jun 2009|
Bibliographical noteFunding Information:
Acknowledgments Supported by: U01CA062491 “Early Clinical Trials of Anti-Cancer Agents with Phase I Emphasis” NCI; CTEP Translational Research Initiative Funding 24XS090, and 1ULRR025011. Clinical and Translational Science Award of the National Center for Research Resources, NIH; and NIH grant T32 CA009614. Physician Scientist Training in Cancer Medicine (Dr. Attia).
- 3-Aminopyridine-2-carboxaldehyde thiosemicarbazone
- Automated quantitative immunohistochemistry (AQUA)
- Quantitative real time PCR
- Ribonucleotide reductase
ASJC Scopus subject areas
- Cancer Research
- Pharmacology (medical)